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Kidney disease has reached epidemic proportions
worldwide. Although the magnitude of the disease has
been better defined in developed countries, there is in-
creasing evidence that kidney disease burden is as great
in developing countries whose infrastructure can least
support management of the disease. In developed coun-
tries, especially in the United States, racial and ethnic
minorities and underserved communities bear a dispro-
portionate burden of the disease [1, 2]. However, kidney
disease is but one of the serious health conditions that
disproportionately afflict these communities. In spite of
the unprecedented scientific advances in biomedical re-
search over the past several decades, which have dramat-
ically improved the public health in developed countries,
many underserved communities in developed countries
and most of the population in developing countries have
not benefited equally. These populations experience a dis-
parate burden of illness, disability, and premature death
[3]. A complex interaction of genetic, biologic, cultural,
and socioeconomic factors, the environment, and specific
health behaviors seems to be responsible for a significant
proportion of the health disparities in these communities
[4].
In the United States, the health disparities that afflict
racial and ethnic minorities and other underserved com-
munities are not limited to a few disease categories. They
apply to a broad spectrum of diseases that include, for ex-
ample, cancer, cardiovascular diseases, stroke, diabetes,
human immunodeficiency virus (HIV)/acquired immune
deficiency syndrome, other infectious diseases, and infant
mortality.
These communities also exhibit increases in key risk
factors for the development of chronic kidney disease
when compared with the Caucasian population [4]. For
example, Hispanic Americans are twice as likely to die
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from diabetes; American Indians and Alaska Natives
have a diabetes rate more than twice that of Caucasians;
more than 65% of African American and Mexican Amer-
ican women are overweight as defined by a body mass in-
dex above 25; more than 10% non-Hispanic black women
in the age group of 40 to 60 years are severely obese,
with BMI over 40; American Indian children have obe-
sity rates more than twice as high as the rest of the
population; and Hispanic Americans also have higher
rates of obesity and high blood pressure than Caucasians
[5].
In 1973, the estimated number of beneficiaries in the
US end-stage renal disease (ESRD) program was approx-
imately 10,000. This number has dramatically increased
to a period prevalence of 512,574 treated patients with
ESRD in 2002. The incidence has also progressively in-
creased and 100,359 new cases were treated in 2002. The
incidence by race (adjusted for age, gender, and cause of
renal disease) was 256 per million population for Cau-
casians compared with 982 for African Americans, 514
for American Indians and Alaska Natives, and 344 for
Asians and Pacific Islanders. The reported incidence rate
in Hispanic Americans in 2002 was 481 per million pop-
ulation [6].
Two diseases, namely diabetes mellitus (predominantly
type 2) and hypertension, cause approximately 70% of
all new adult ESRD cases in the United States. Glomeru-
lonephritis and cystic kidney diseases contribute about
10% each. However, other “rarer” diseases causing
ESRD, such as HIV, are also important contributors, es-
pecially in African Americans.
The greatest incidence and prevalence rates of treated
ESRD are reported in the United States and Japan, with
incidence rates in excess of 300 cases per million popula-
tion. However, most developed nations have experienced
staggering increases in both incidence and prevalence
rates. More frightening and potentially devastating are
the reports of alarming increases in renal disease in devel-
oping countries whose economies simply cannot support
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the bare necessities of disease treatment. The greatest
burden of kidney disease has been in indigenous peoples
worldwide. Although the exact explanation is yet to be
found, it has been observed that transition of these popu-
lations from their traditional ways of life, including diets,
to a Western European lifestyle may have resulted in ac-
celerated development of diseases such as diabetes and
hypertension, which ultimately lead to kidney damage
[7]. There is also the question of an increased prevalence
of an “underdeveloped” kidney in indigenous popula-
tions, which has been reported to be related to genetic
and/or environmental influences [8].
The early effects of diabetes on the kidneys include
microalbuminuria and hyperfiltration. Subsequently, the
damage progresses to gross proteinuria and a relent-
less decrease in glomerular filtration rate to end stage.
Some investigators suggest that intervening early in the
course of the disease would be more effective than af-
ter the disease has been established. Several landmark
studies have shown that down modulation of the renin-
angiotensin-aldosterone axis, such as with angiotensin-
converting enzyme inhibitors (ACEI) and angiotensin
receptor blockers, is effective in reducing progression of
the nephropathy of type 2 diabetes [9, 10, 11]. This has
significant implications for developing countries whose
economies cannot adequately support chronic renal re-
placement therapy.
It has been suggested that the high incidence of hyper-
tensive kidney disease in high risk populations may be a
result of damage from severe essential hypertension po-
tentiated by environmental nephrotoxins, use of illicit or
prescribed drugs, or other factors [12–15]. Until recently,
there was no effective way to halt progression to end stage
once the disease developed. However, the results of the
recently completed African American Study of Kidney
Disease and Hypertension clinical trial has shown that
progression can be slowed even in the relatively advanced
stage of the disease by the use of ACEI [16]. These results
have important implications for developing countries
since these simpler therapeutic regimens can perhaps be
more readily applied to hypertensive individuals in these
countries.
The current epidemic of infection with HIV, especially
in many developing countries, has resulted in another im-
portant cause of chronic kidney disease and ESRD [17–
19]. Recent advances in antiretroviral and other therapies
(including the use of ACEI) have shown that this disease
can be controlled. However, the expense of these thera-
pies constitutes a significant roadblock in the successful
implementation in developing countries.
Early in the development of renal replacement therapy
(RRT), the focus was primarily on correcting acid-base,
fluid and electrolyte disorders. Dialysis was the outcome
of those early considerations. Therefore, it is not surpris-
ing that although dialysis has resulted in saving the life
of the patient with ESRD from immediate death, neither
the quality of life nor the expected remaining life years
are returned to the pre-renal failure level. Furthermore,
this technology as a chronic RRT can only be supported
by economies of developed countries, and is, therefore, of
little benefit to patients in developing countries. A suc-
cessful renal transplant, on the other hand, returns the
patient to near-normal quality of life and lifespan. How-
ever, the technical and economic requirements, and the
high risks attendant on chronic immunosuppression ren-
der this modality of RRT unattainable in most developing
countries.
The recently held satellite meeting in Ensenada, Mex-
ico, emphasized the spectrum and impact of kidney dis-
ease in racial and ethnic minorities and the indigenous
populations of the Americas. The summaries of the pre-
sentations are highlighted in the articles that follow. The
organizing committee hopes that these articles will help
to define the magnitude of the issues and serve as a foun-
dation for relevant research programs, treatment algo-
rithms, and social and economic policies.
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